|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.33 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
14,410,000 |
| Market
Cap: |
4.80(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3333 - $0.3333 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,262 |
| Total Buy Value |
$0 |
$0 |
$0 |
$197,404 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lowe David George |
Director |
– • – |
2009-06-10 |
4 |
S |
$3.96 |
$142,448 |
I/I |
(36,000) |
386,000 |
|
- |
|
| Skyline Venture Partners Qualified Purchaser Fund |
Former 10% owner |
– – – |
2009-06-09 |
4 |
S |
$3.99 |
$189,392 |
D/D |
(47,500) |
422,000 |
|
- |
|
| Lowe David George |
Director |
– • – |
2009-06-09 |
4 |
S |
$3.99 |
$189,392 |
I/I |
(47,500) |
422,000 |
|
- |
|
| Skyline Venture Partners Qualified Purchaser Fund |
Former 10% owner |
– – – |
2009-06-08 |
4 |
S |
$4.21 |
$276,388 |
D/D |
(65,708) |
469,500 |
|
- |
|
| Lowe David George |
Director |
– • – |
2009-06-08 |
4 |
S |
$4.21 |
$276,388 |
I/I |
(65,708) |
469,500 |
|
- |
|
| Lowe David George |
Director |
– • • |
2009-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(342,375) |
535,208 |
|
- |
|
| Skyline Venture Partners Qualified Purchaser Fund |
10% Owner |
– – • |
2009-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(342,375) |
535,208 |
|
- |
|
| Roshko Peter |
10% Owner |
– – • |
2009-04-06 |
4 |
A |
$0.00 |
$0 |
I/I |
549 |
549 |
|
- |
|
| Roshko Peter |
10% Owner |
– – • |
2009-04-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,292) |
44,715 |
|
- |
|
| Roshko Peter |
10% Owner |
– – • |
2009-04-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(49,708) |
675,403 |
|
- |
|
| Falberg Kathryn E |
CFO and COOOfficer |
• – – |
2009-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,000 |
|
- |
|
| Formela Jean Francois |
Director |
– • • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,402,163 |
|
- |
|
| Grais Linda S |
Director |
– • – |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
702,698 |
|
- |
|
| Bristow Michael R |
Chief Science and Med. Officer |
• • – |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
272,677 |
|
- |
|
| Skyline Venture Partners Qualified Purchaser Fund |
10% Owner |
– – • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
877,583 |
|
- |
|
| Roshko Peter |
10% Owner |
– – • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
48,007 |
|
- |
|
| Roshko Peter |
10% Owner |
– – • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
725,111 |
|
- |
|
| Lowe David George |
Director |
– • • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
877,583 |
|
- |
|
| Atlas Venture Associates Vii, L.p. |
10% Owner |
– – • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,402,163 |
|
- |
|
| Zabriskie John L |
Director |
– • – |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
29,180 |
|
- |
|
| Brewer Richard B |
President and CEOOfficer |
• • – |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,490 |
|
- |
|
| Ozeroff Christopher David |
EVP & General CounselOfficer |
• – – |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
79,388 |
|
- |
|
| Bendekgey E Lee |
CFO and Treasurer |
• – – |
2008-11-28 |
5 |
A |
$5.27 |
$2,808 |
D/D |
533 |
1,502 |
|
- |
|
| Bendekgey E Lee |
CFO and Treasurer |
• – – |
2008-08-29 |
5 |
A |
$8.42 |
$2,811 |
D/D |
334 |
1,502 |
|
- |
|
| Love Ted W |
Director |
– • – |
2008-05-30 |
5 |
A |
$13.09 |
$1,924 |
D/D |
147 |
3,580 |
|
- |
|
240 Records found
|
|
Page 7 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
